Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Study ID
- NCT02257424
- Phase
- PHASE1/PHASE2
- Status
- Completed
Conditions
- Advanced BRAF Mutant Melanoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Trametinib 2 mg daily — DRUG
- hydroxychloroquine (HCQ) — DRUGhydroxychloroquine (HCQ) is 600 mg orally every 12 hours
- dabrafenib 150 mg orally twice a day — DRUG
Study Details
The primary purpose of this study is to determine the maximum tolerated dose (MTD) and preliminary safety of hydroxychloroquine (HCQ) when administered in conjunction with oral dabrafenib and trametinib (D+T) in patients with advanced BRAF mutant melanoma.
Key Dates
- Start date
- Oct 31, 2014
- Status verified
- Jan 2022
- Primary completion
- Oct 31, 2021
- Completion
- Oct 31, 2021
Study Design
- Enrollment
- 50 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Other: Phase 1/2
Primary Outcome Measure
Phase 1: To determine the maximum tolerated dose [ Time Frame: 5 weeks ]
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Robert H. Lurie Comprehensive Cancer Center | Chicago | Illinois | 60611 | - |
| Washington University School of Medicine | St Louis | Missouri | 63110 | - |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | - |
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | - |